C4 Therapeutics to Unveil Cemsidomide Biomarker Data at IMS Meeting
Event summary
- C4 Therapeutics will present new biomarker data on cemsidomide's immunomodulatory effects in combination with dexamethasone at the 23rd IMS Annual Meeting.
- The data characterize immune effects on T cells and NK cells from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM).
- Poster presentation scheduled for September 25, 2026, during the IMS meeting in Glasgow, Scotland.
- Cemsidomide is an investigational MonoDAC® degrader targeting IKZF1/3 transcription factors in multiple myeloma.
The big picture
C4 Therapeutics' presentation at the IMS Annual Meeting underscores the growing focus on targeted protein degradation in oncology. The biomarker data could position cemsidomide as a key player in the relapsed/refractory multiple myeloma space, where durable responses remain a critical unmet need. The strategic significance lies in the potential to combine cemsidomide with immune-based therapies, aligning with broader industry trends toward immuno-oncology combinations.
What we're watching
- Clinical Validation
- How the biomarker data will influence the perception of cemsidomide's potential as a combination therapy in RRMM.
- Regulatory Pathway
- Whether the Phase 1 trial results will accelerate cemsidomide's development timeline.
- Competitive Positioning
- The pace at which C4 Therapeutics can differentiate cemsidomide in the crowded multiple myeloma treatment landscape.
Related topics